---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-027874"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2025-08-27T23:59:59+00:00"
generated_at: "2026-05-17T09:43:35.078763+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# UroGen shareholders approve 2.75M share increase under 2017 equity plan and new compensation policy

## Summary
- Shareholders approved amendment to 2017 Equity Incentive Plan, authorizing 2,750,000 additional ordinary shares.
- Shareholders approved Amended and Restated Non-Employee Director and Officer Compensation Policy.
- All seven director nominees elected: Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Leana Wen, Daniel Wildman.
- Advisory vote on executive compensation approved (18.85M for); one-year frequency for future say-on-pay votes selected.
- PricewaterhouseCoopers LLP ratified as independent auditor with 32.9M votes in favor.

## SEC filing metadata
- accession: 0001437749-25-027874
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2025-08-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774925027874/0001437749-25-027874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774925027874/urgn20250826_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-027874
- JSON: https://secwatch.observer/filing/0001437749-25-027874.json
- Plain text: https://secwatch.observer/filing/0001437749-25-027874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.